All Updates

All Updates

icon
Filter
Partnerships
XtalPi expands Signet collaboration to include new drug program
AI Drug Discovery
Oct 27, 2021
This week:
Partnerships
Microsoft and BlackRock partner to launch USD 30 billion AI data center investment fund
Machine Learning Infrastructure
Yesterday
Funding
Limitless Labs raises USD 3 million in pre-seed funding to develop prediction market
Web3 Ecosystem
Yesterday
Product updates
Google Cloud launches Blockchain RPC service for Web3 developers
Web3 Ecosystem
Yesterday
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Machine Learning Infrastructure
Yesterday
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Generative AI Infrastructure
Yesterday
Partnerships
Climeworks partners with Terraset to enable philanthropic support for carbon removal
Carbon Capture, Utilization & Storage (CCUS)
Sep 17, 2024
Funding
8 Rivers secures investment from JX Nippon to commercialize DAC technology
Carbon Capture, Utilization & Storage (CCUS)
Sep 17, 2024
Product updates
ProAmpac launches enhanced online pouch configurator MAKR by DASL for custom flexible packaging prototypes
Smart Packaging Tech
Sep 17, 2024
Funding
M&A
Majority stake in Bollegraaf Group acquired by Summa Equity for EUR 800 million
Waste Recovery & Management Tech
Sep 17, 2024
Partnerships
NASA awards Intuitive Machines contract for near-space network services
Space Travel and Exploration Tech
Sep 17, 2024
AI Drug Discovery

AI Drug Discovery

Oct 27, 2021

XtalPi expands Signet collaboration to include new drug program

Partnerships

  • American-Chinese, Google-backed AI drug discovery company XtalPi has expanded its collaboration agreement (previously entered in 2020) with US-based oncology drug discovery company Signet Therapeutics to include a new drug program. The terms and financial details of the collaboration have not been disclosed. 

  • The new collaborative program will discover novel drug candidates against a novel cancer target identified by Signet, by leveraging XtalPi’s AI platform combined with Signet's unique novel organoid disease model platform.

  • The initial collaboration between the two parties resulted in the identification of novel preclinical candidates for a new gastric cancer target—in approximately six months—which are approaching clinical trials.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.